Showing 5481-5490 of 8791 results for "".
- DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kithttps://practicaldermatology.com/news/dermtech-receives-health-canada-approval-to-market-pla-and-non-invasive-biopsy-kit/2457937/DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s c
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t
- Microarray Skin Patch May Help Solve Antibiotic Resistance Crisishttps://practicaldermatology.com/news/microarray-skin-patch-may-help-solve-antibiotic-resistance-crisis/2457939/Skin microarray patches that administer drugs directly into the bloodstream through thousands of individual “microneedles” may help solve the antibiotic resistance crisis. “One of the biggest problems is that the huge majority of the drugs are taken orally. This me
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil
- UCB: Bimekizumab Shows Joint and Skin Responses in Psoriatic Arthritishttps://practicaldermatology.com/news/ucb-bimekizumab-shows-joint-and-skin-responses-in-psoriatic-arthritis/2457945/UCB has announced that the Phase 2b BE ACTIVE study met the primary objective of establishing dose response for bimekizumab with statistical significance. The study also demonstrated robust efficacy in psor
- FDA Accepts NDA for Allergan, Paratek Acne Drughttps://practicaldermatology.com/news/fda-accepts-nda-for-allergan-paratek-acne-drug/2457946/The U.S. Food and Drug Administration accepted a New Drug Application (NDA) to review SeysaraTM(sarecycline) for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older, Allergan plc and Parate
- Aclaris Initiates Pilot Clinical Trial of ATI-50002 Topical for Vitiligohttps://practicaldermatology.com/news/aclaris-initiates-pilot-clinical-trial-of-ati-50002-topical-for-vitiligo/2457947/Aclaris Therapeutics, Inc., has initiated a Phase 2 open-label clinical trial of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002 Topical) and an investigational drug, for the potential treatment of non-segmental vitiligo of the face. This trial will evaluate the safety, t
- Biofrontera Files Investigational NDA for Phase 3 Trial of Ameluz for BCChttps://practicaldermatology.com/news/biofrontera-files-investigational-nda-for-phase-3-trial-of-ameluz-for-bcc/2457948/Biofrontera AG has filed an investigational new drug (IND) application with the FDA for its proposed Phase 3 study protocol to evaluate Ameluz® photodynamic therapy (PDT) for the treatment of superficial basal cell carcinoma. The IND filing is in accordance with the advice provided by F
- NPF Launches New Resource for Youth with Psoriasis, Psoriatic Arthritishttps://practicaldermatology.com/news/npf-launches-new-resource-for-youth-with-psoriasis-psoriatic-arthritis/2457949/Our Spot, a new resource launched by The National Psoriasis Foundation (NPF), provides resources for kids and teens living with psoriasis and psoriatic arthritis. The program includes a
- SK Breakthrough: FDA Approves Eskata (hydrogen peroxide) Topical Solution from Aclarishttps://practicaldermatology.com/news/sk-breakthrough-fda-approves-eskata-hydrogen-peroxide-topical-solution-from-aclaris/2457950/The FDA has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) from Aclaris Therapeutics, Inc. for the treatment of seborrheic keratoses (SKs). SKs are non-cancerous skin growths that affect more than 83 million American adults. They may frequently appear in highly visible are